These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1133166)

  • 21. Pharmacokinetics of gentamicin in children with nephrotic syndrome.
    González-Martin G; Bravo I; Vargas H; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):555-8. PubMed ID: 3781676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat.
    O'Leary TD; Sansom LN
    J Pharmacol Exp Ther; 1981 Mar; 216(3):613-6. PubMed ID: 6782238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.
    Tiula E; Tallgren LG; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):545-52. PubMed ID: 3429058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma and urinary antithrombin III in the nephrotic syndrome in adults].
    Antelin CH; Gouault-Heilmann M; Levent M; Bernard D; Ruszniewski P; Lagrue G
    Ann Med Interne (Paris); 1983; 134(8):713-6. PubMed ID: 6666909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome.
    Frey FJ; Frey BM
    Am J Kidney Dis; 1984 Mar; 3(5):339-48. PubMed ID: 6702820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diphenylhydantoin: correlation between protein binding and albumin concentration.
    Gugler R; Azarnoff DL; Shoeman DW
    Klin Wochenschr; 1975 May; 53(9):445-6. PubMed ID: 1152355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of drugs in rabbits with experimental acute renal failure.
    Van Peer A; Belpaire F; Bogaert M
    Pharmacology; 1978; 17(6):307-14. PubMed ID: 733890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Furosemide binding to human albumin and plasma of nephrotic children.
    Prandota J; Pruitt AW
    Clin Pharmacol Ther; 1975 Feb; 17(2):159-65. PubMed ID: 235396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between metronidazole and drugs eliminated by oxidative metabolism.
    Jensen JC; Gugler R
    Clin Pharmacol Ther; 1985 Apr; 37(4):407-10. PubMed ID: 3979002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proceedings: Pharmacokinetics of drugs in patients with nephrotic syndrome.
    Azarnoff DL; Gugler R; Shoeman DW; Huffman DH; Cohlmia J
    Arzneimittelforschung; 1976; 26(6):1267-8. PubMed ID: 989463
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

  • 32. Distribution of antipyrine, phenylbutazone and phenytoin in experimental renal failure.
    Van Peer AP; Belpaire FM; Rosseel MT; Bogaert MG
    Pharmacology; 1981; 22(2):139-45. PubMed ID: 7208595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of vitamin C to affect the pharmacokinetic profile of antipyrine in man.
    Wilson JT; Boxtel CJ; Alvan G; Sjoqvist F
    J Clin Pharmacol; 1976; 16(5-6):265-70. PubMed ID: 1262536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clofibrate kinetics after single and multiple doses.
    Gugler R; Hartlapp J
    Clin Pharmacol Ther; 1978 Oct; 24(4):432-8. PubMed ID: 688733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of pharmacodynamics and pharmacokinetics of clofibrate for the purpose of selection of optimal course of treatment of ischemic heart disease].
    Kukes VG; Senik EA; Gneushev ET; Utlinskaia MG; Nasonov AS
    Ter Arkh; 1979; 51(12):57-61. PubMed ID: 538720
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma protein binding of carbamazepine.
    Hooper WD; Dubetz DK; Bochner F; Cotter LM; Smith GA; Eadie MJ; Tyrer JH
    Clin Pharmacol Ther; 1975 Apr; 17(4):433-40. PubMed ID: 1122684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on vitamin D binding protein in the nephrotic syndrome.
    Colston K; Williams NJ; Cleeve HJ
    Clin Chem; 1985 May; 31(5):718-21. PubMed ID: 4039229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clofibrate-induced complications in renal disease: a case report.
    Pokroy N; Ress S; Gregory MC
    S Afr Med J; 1977 Nov; 52(20):806-8. PubMed ID: 204061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The separation of unbound prednisolone in plasma by centrifugal ultrafiltration.
    Miller PF; Wheeldon J; Brocklebank JT
    J Pharm Pharmacol; 1987 Nov; 39(11):939-41. PubMed ID: 2892921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A vascular permeability factor in lymphocyte culture supernants from patients with nephrotic syndrome. II. Pharmacological and physicochemical properties.
    Lagrue G; Branellec A; Blanc C; Xheneumont S; Beaudoux F; Sobel A; Weil B
    Biomedicine; 1975 Feb; 23(2):73-5. PubMed ID: 168931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.